Sinopharm CNBG’s Shanghai Institute of Biological Products has received a batch release certificate for its inactivated split‑virus influenza vaccine, marking the product’s market launch for the 2026–27 season. The vaccine was developed to the WHO‑re

2026-07-22

Sinopharm CNBG’s Shanghai Institute of Biological Products has received a batch release certificate for its inactivated split‑virus influenza vaccine, marking the product’s market launch for the 2026–27 season. The vaccine was developed to the WHO‑recommended 2026–27 Northern Hemisphere influenza strains.